Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 16/20 | 1.00 |
| ▸ | PIK3C2A | O00443 | 2/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 2/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Torin1 SCHEMBL29350222 | 1.00 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| Torin1 SCHEMBL29357575 | 1.00 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| Torin1 SCHEMBL29499920 | 1.00 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6876203 | 0.95 | MTOR (0.91) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6878217 | 0.93 | MTOR (0.87) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL7919237 | 0.92 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6874967 | 0.91 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6877194 | 0.91 | MTOR (0.84) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6877181 | 0.91 | MTOR (0.86) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6874774 | 0.91 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196676-A1 | TREATING TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2023073054-A1 | COMPOSITIONS AND METHODS USING AN AUTOPHAGY INDUCER TO ENHANCE INTERMITTENT FASTING | Société des Produits Nestlé S.A. (CH) | 2023-05-04 | — | — | WO | claimed |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | THE BROAD INSTITUTE, INC. (US) | 2022-10-18 | — | — | US | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3352755-B1 | TOPICAL COMPOSITION COMPRISING RAPAMYCIN FOR USE IN TREATING OR PREVENTING SEBORRHEIC KERATOSIS OR ACTINIC KERATOSIS | UNIV DREXEL (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240382614-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides for Drug Delivery Applications | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | MOORMAN NATHANIEL (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | MOORMAN NATHANIEL (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2010044885-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | EIF2AK2, MTOR, EIF4EBP1 | MTOR 2/4885PIK3C2A 271/4885PIK3C2B 329/4885 |
| US-20240382614-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides for Drug Delivery Applications | ANXA11, ANXA1, IAPP | MTOR 4558/4885PIK3C2A 2212/4885PIK3C2B 1889/4885 |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3C2A 18/4885PIK3C2B 16/4885 |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | SLC2A2, SLC2A1, SLC5A2 | MTOR 3599/4885PIK3C2A 2622/4885PIK3C2B 2870/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | MTOR 4841/4885PIK3C2A 2442/4885PIK3C2B 1892/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | MTOR 4823/4885PIK3C2A 1969/4885PIK3C2B 1450/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | MTOR 426/4885PIK3C2A 673/4885PIK3C2B 603/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3C2A 18/4885PIK3C2B 16/4885 |
| US-20240325398-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | MTOR 24/4885PIK3C2A 108/4885PIK3C2B 119/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | MTOR 4841/4885PIK3C2A 2442/4885PIK3C2B 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.